Purpose This study compared the antitumor activity and the pharmacological proWle of gimatecan given orally and irinotecan (CPT-11) on pediatric tumor xenografts. Experimental design Gimatecan was tested in two neuroblastoma cell lines (SK-N-DZ and SK-N-(BE)2c) and on TE-671 rhabdomyosarcoma cells using two diVerent schedules. We characterized its pharmacokinetic proWle in nude mice bearing human SK-N-DZ and TE-671 cell lines. Results Gimatecan appears to have high plasma disposition. The drug was present in plasma almost completely as the intact lactone form and showed substantial activity in all tumor models. Prolonged daily treatment with low doses of gimatecan produced signiWcant tumor regression in all tumor xenografts. Conclusion The antitumor activity and the promising pharmacological proWle indicate gimatecan as an excellent candidate for clinical treatment of pediatric tumors.
Introduction
Camptothecins are a class of antineoplastic agents with a wide spectrum of antitumor activity and are among the most eVective drugs for the treatment of solid tumors. Their mechanism of action involves the inhibition of DNA topoisomerase I [1] . DNA topoisomerases are enzymes, which modify DNA topology by transiently breaking strands of the DNA, and are particularly important in replication and transcription. Camptothecin and its derivatives stabilize the cleavable complex between topoisomerase I and single-strand DNA that inhibits the DNA relegation [2] .
Topotecan and irinotecan (CPT-11), which are derivatives of camptothecins, are nowadays regularly employed in clinical practice. CPT-11 is a water-soluble analog that has shown signiWcant activity against a number of diVerent tumor types in preclinical and in clinical trials of patients with colon, stomach, pancreas and non-small-cell lung cancers [3] [4] [5] . Moreover, it has been demonstrated that neuroblastoma xenografts are highly sensitive to CPT-11 [6] . The active metabolite of CPT-11, SN-38, stabilizes a ternary complex between the nuclear enzyme topoisomerase I and double-stranded DNA [7] . As reported by Santos et al., CPT-11 shows marked antitumoral activity against pediatric xenografts in preclinical studies [8, 9] . Topotecan is used as a standard treatment in ovarian cancer, and it was recently reported to be eVective in a small percentage of patients with relapsed or refractory neuroblastoma [10] [11] [12] . However, camptothecins suVer some problems in the pharmacological proWle, such as reversibility of the drug-target interaction, the opening of the lactone ring and subsequent binding with serum albumin [13] [14] [15] [16] .
Recently, new camptothecins substituted at position 7 with lipophilic chains have been synthesized with the purpose to help the stabilization of the lactone form that is responsible for the pharmacological activity [13, 17] . One of these, gimatecan (Fig. 1) , is particularly interesting, because it oVers strong cytotoxic potency, due to topoisomerase I inhibition, enhanced accumulation in cells and persistent stabilization of the cleavable complex [18] [19] [20] [21] . Moreover, the recently described breast cancer resistance-associated protein (BCRP) does not recognize gimatecan. BCRP is important in cellular resistance to topotecan, irinotecan and mitoxantrone [22] . Gimatecan's potency is related to a larger number of DNA strand breaks compared to other camptothecin analogs, and it is particularly eVective against some human tumor xenografts derived from adult tumors [19] . Finally, this drug is highly bioavailable by the oral route, which is of particular interest especially in pediatric patients, and is therefore suitable for prolonged daily administration.
The aim of the present study was to evaluate the antitumor activity and the pharmacokinetics of gimatecan given orally to pediatric tumor xenografts.
Materials and methods

Drugs
Gimatecan and SN-38 were kindly provided by Sigma-Tau, Pomezia, Rome, Italy. The drugs were dissolved in dimethyl sulfoxide (DMSO) to make the stock solutions (10 mg/ml for gimatecan and 10 mM for SN-38), which were stored in small aliquots at ¡20°C, protected from light. Irinotecan (CPT-11, Campto ® , PWzer Italia, Latina, Italy) for in vivo studies was dissolved in sterile distilled water.
Cell cultures and culture conditions
The human neuroblastoma cell lines (SK-N-DZ, SK-N-BE(2)c) and human rhabdomyosarcoma TE-671 cells were purchased from the American Type Culture Collection (Rockville, MD, USA). Cells were maintained in RPMI 1640 medium, supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine and penicillin-streptomycin at 37°C in 5% CO 2 .
Cell sensitivity Cell sensitivity to gimatecan and SN-38 was assessed by 5-day MTT assay. Cells were seeded at the appropriate density in 96-well plates, grown overnight and exposed to serial dilutions of the two drugs. After 72 h of incubation, 150 g/well MTT was added for 3 h at 37°C. Formazan products were solubilized with 200 l of DMSO, and absorbance was detected at 540 nm (reference wavelength 690 nm) using a microplate spectrophotometer. Cytotoxicity was assessed from dose-response curves as the IC 50 , which is the drug concentration of drug required to inhibit by 50% cell growth. All experiments were run in triplicate.
Mice
CD1 nu/nu male nude mice (Charles River, Calco, Italy) at 5 weeks of age were used. All animal investigations complied with the guidelines of the Istituto Superiore di Sanità (Rome, Italy) on experimental neoplasia in animals. The animals were maintained under speciWc pathogen-free conditions.
Pediatric xenografts and tumor growth
We evaluated the eVects of gimatecan and CPT-11 in two human pediatric neuroblastoma cell lines (SK-N-DZ, SK-N-BE(2)c) and in the human rhabdomyosarcoma cell line (TE-671), growing as xenografts in nude mice; 20 £ 10 6 cells were injected subcutaneously for SK-N-DZ and SK-N-BE(2)c and 1.5 £ 10 6 cells for TE-671 in both Xanks. Two diVerent schedules were used: qdx5/wx4w and q4dx4. In the Wrst schedule, gimatecan was administered 0.25 mg/ kg/d orally, whereas CPT-11 injected i.p. at 10 mg/kg/d; in the second schedule, gimatecan and CPT11 were administered, respectively, 1.25 mg/kg/d and 50 mg/kg/d. Each control or drug-treated group consisted of 8-10 mice. The eYcacy of drug treatment was assessed as percentage tumor volume inhibition (TVI%) in treated (T) versus control (C) mice according to the formula: 100 ¡ (T/C £ 100). Log 10 Cell Kill (LCK):(T ¡ C)/3.32 £ DT where T is the mean time (days) required for treated tumors and C for the control to reach an established volume (400 mg), and DT is the mean Doubling Time of control tumors.
Complete regression (CR) was deWned as tumor disappearance lasting at least 10 days during or after treatment [6, 21] .
Student's test (two-tailed) was applied to compare in vivo tumor growth between treated and control groups; the diVerences were considered statistically signiWcant at P < 0.05. For statistical analyses, we randomly selected one of the bilateral tumors in each animal, because the growth and the responses to the treatment were similar in both Xanks.
Pharmacokinetic study
Mice bearing neuroblastoma and rhabdomyosarcoma xenografts were treated orally with single or repeated (5 days) doses of 0.25 mg/kg of gimatecan. At diVerent times (0, 0.25, 0.5, 1, 2, 4, 8 and 24 h) after the single dose and after the last dose on day Wve, three mice per time point were sacriWced. The tumors were removed and the blood collected into heparinized tubes by cardiac puncture. Plasma was obtained by centrifugation at 3,000 rpm at 4°C and stored frozen, together with the tumors, at ¡20°C until analysis.
A highly speciWc and sensitive validated HPLC method was used to determine total gimatecan (lactone plus hydroxyacid form) and its major metabolite, the t-butyl hydroxy derivative in mouse plasma samples and tumors [23] . The method, originally developed in human plasma, is based on on-line column solid-phase extraction under acid conditions of the analytes from plasma after addition of the internal standard (IS, 20-O-butirryl-camptothecin) chromatographic separation under isocratic conditions and Xuorimetric detection. The limit of quantiWcation is 0.5 ng/ml for both analytes.
Tumors were homogenized and extracted in four volumes (p:v) of 0.1 N HCl:CH 3 CN (1/10), centrifuged, the organic phase was mixed with 50 ng of IS and diluted 1:1 with 0.1% HCOOH:CH3CN (1:1). After centrifugation for 10 min at 4,000 rpm, portions of the supernatants were injected for HPLC analysis.
In a second experiment to determine the presence of the intact lactone form of gimatecan, a modiWcation of the present HPLC method was introduced, and the intact lactone form was assayed in plasma of CD1 male mice [23] . Analysis was carried out without acidiWcation of the plasma samples and consisted of the addition of 100 l of bi-distilled water to 100 l of plasma and of IS. Chromatographic separation was achieved under neutral pH conditions with a mobile phase of 50% acetonitrile in bi-distilled water. Samples were quantiWed using the same standard calibration curve and quality control samples prepared for the assay of total gimatecan with extraction under acid conditions, but using neutral pH chromatographic separation with a mobile phase of 50% acetonitrile in bi-distilled water.
The analytical reference standard of gimatecan (batch No 532/68) was provided by Antibioticos S.p.A. The analytical reference standard of 20-O-butirryl-camptothecin (batch No EM/1/1) used as IS was provided by Sigma-Tau.
Results
In vitro growth inhibition
The cytotoxic eVects of gimatecan and SN-38 were evaluated in vitro by the MTT assay after 3 days exposure. As shown in Table 1 , gimatecan was substantially more potent than SN-38 in all cell lines. The neuroblastoma cell lines SK-N-DZ and SK-N-(BE)2c showed particularly high sensitivity to gimatecan in comparison with the rhabdomyosarcoma cell line (up to 68-and 13-fold). The SN-38 concentrations required to inhibit cell growth by 50% in neuroblastoma cells were 900 and 600 nM for SK-N-DZ and SK-N-(BE)2c, and the IC 50 for TE-671 cells was 2100 nM.
Xenograft growth inhibition
We compared the eVects of gimatecan (p.o.) and irinotecan on pediatric tumors from neuroblastoma (SK-N-DZ and SK-N-BE(2)c) and rhabdomyosarcoma (TE-671) (Fig. 2) . Two diVerent schedules were used: qdx5/wx4w and q4dx4. With both schedules, the maximum tolerated doses (MTD) were 5 mg/kg for gimatecan and 200 mg/kg for CPT-11. The antitumor activity of the drugs is shown in Fig. 2 . With the qdx5/wx4w schedule, gimatecan produced a statistically signiWcant tumor regression in all tumor xenografts (P at least <0.008). In SK-NDZ model, a complete disappear of tumor was observed in 100% of mice. As no tumor regrowth was observed up to 15 days from the end of treatment, this was considered a CR. In a prolonged observation up to 72 days, no tumor regrowth was observed in the two NB models, whereas in the rhabdomyosarcoma xenograft, there was a high incidence of tumor regrowth (data not shown). CPT-11 induced regression of the tumor on SK-N-DZ and TE-671 xenografts, but was completely ineVective against SK-N-(BE)2c xenografts. Consistently with the With the q4dx4 schedule gimatecan completely inhibited the tumor growth only of the SK-N-DZ xenografts, and the TE-671 and SK-N-(BE)2c xenografts were less sensitive, showing signiWcant (P < 0.04) but not complete tumor regression (TVI% and LCK: 78 and 2.3 for TE-671; 92 and 1.1 for SK-N-(BE)2c). CPT-11 had diVerent eVects in the three models: a complete response was achieved only on SK-N-DZ tumor xenografts, and TE-671 xenografts regrew at the end of the treatment. It had no antitumoral activity on SK-N-(BE)2c xenografts.
Gimatecan was generally well tolerated, with no signs of acute or delayed toxicity. An approximately 10-15% reduction in body weight was observed at the end of the treatment (data not shown), but this was reversible upon cessation of treatment. Figures 3 and 4 show the plasma levels and the tumor distribution of gimatecan in mice bearing SK-N-DZ neuroblastoma and TE-671 rhabdomyosarcoma after oral doses of 0.25 mg/kg. The main pharmacokinetic parameters are listed in Table 2 .
Pharmacokinetics of gimatecan
After the single dose, gimatecan achieved peak plasma concentration and AUC of 72.1 ng/ml and 269.3 ng/ml £ h in mice with sarcoma and 26.8 ng/ml and 256.6 ng/ml £ h in mice with neuroblastoma. In both cases, the drug was undetectable in plasma at 24 h.
Gimatecan achieved higher and more persistent concentrations in the tumor tissue than in plasma and distributed more extensively in SK-N-DZ tumor than in TE-671 tumor, with ratios of tumor AUC to plasma AUC of 5.2 and 1.5 for SK-N-DZ and TE-671 bearing mice, respectively. In the SK-N-DZ tumor, these concentrations were at all times¸10 ng/g (22 nM), 12 times the IC 50 (Table 1) , whereas in TE-671 tumor, gimatecan achieved concentrations superior to the IC 50 (115 nM) only up to 2 h. After the repeated treatment, plasma levels of gimatecan were higher in both groups of mice than after a single dose. The drug disappeared from plasma with a half-life of 5-9.5 h, being still detectable at 24 h in TE-671 mice, with accumulation in tumor tissue. On day Wve, the gimatecan AUC remained high (1576.9 ng/ml £ h) in SK-N-DZ tumor, and rose threefold in TE-671 tumor (from 399.7 to 1283.2 ng/ml £ h) achieving concentrations in this tumor in the range of 120-200 nM, superior to the IC 50 (Table 1) .
In a separate experiment, using a modiWcation of the HPLC method used to analyze total gimatecan [23] , the intact lactone form was assayed in plasma of mice for 0-6 h after a single dose of 0.25 mg/kg of gimatecan. Figure 5 compares the plasma levels of total gimatecan and the intact lactone; gimatecan was detected in plasma almost completely as the intact lactone form (more than 80%). This is particularly important as this form is responsible for the pharmacological activity of the camptothecins.
Discussion
The present study found that gimatecan was signiWcantly eVective in the treatment of pediatric neuroblastoma and rhabdomyosarcoma grown s.c. in nude mice. On these tumor models, gimatecan was more eVective than CPT-11, used for comparison in inhibiting cell proliferation and tumor growth in vitro and in vivo.
In vitro gimatecan had signiWcantly higher antiproliferative potency than SN-38 on all three cell lines. SK-N-DZ showed higher sensitivity to gimatecan than the rhabdomyosarcoma cell line (up to 68-fold), whereas the sensitivity to SN-38 was similar in both cell lines. These data are comparable with those of a previous study on a panel of neuroblastoma cell lines, despite the low intracellular accumulation of gimatecan [19] .
Gimatecan also showed superior antitumor activity in vivo with two diVerent treatment schedules that appeared well tolerated by mice, with only a 10-15% reduction in body weight at the end of the treatment.
With the qdx5/wx4w treatment, gimatecan produced a complete response in all tumor xenografts. CPT-11 induced complete tumors response in SK-N-DZ and TE-671 xenografts, but was ineVective against SK-N-(BE)2c. With the q4dx4 schedule, gimatecan completely inhibited the growth of SK-N-DZ tumors xenografts, whereas TE-671 and SK-N-(BE)2c xenografts were less sensitive, though they still showed signiWcant regression. The eVects of CPT-11 were diVerent in the three models, with complete regression only on SK-N-DZ, whereas TE-671 xenografts re-grew at the end of the treatment, and no antitumoral activity was observed on SK-N-(BE)2c xenografts.
The in vivo results were supported by pharmacokinetic data showing that gimatecan reached high levels in plasma and in tumor tissues at concentrations that are potentially active in vitro. In the most responsive tumor, the neuroblastoma SK-N-DZ, gimatecan achieved concentrations in tumor tissue that were at least from 2 to 12 times the IC 50 and were measurable throughout the 24-h sampling on both days (1 and 5) of the pharmacokinetic study. In the other tumor model (TE-671), that was less sensitive in vitro and less responsive in vivo, gimatecan reached concentrations higher than the IC 50 , measurable throughout the 8-h sampling only on day 5. It is also to notice that the AUCs we found in mice were three-sixfold lower than the AUC previously reported by Sessa et al. relative to a dose of 4.5 mg/ m 2 (daily 0.9 mg/m 2 ) that correspond to the MTD in humans [24] .
We found that gimatecan had some distinct pharmacological properties, in particular the unique stability of the lactone form in plasma (the form generally considered active as a DNA topoisomerase I poison) that accounts for >80% of the total in mice, diVerently from the other clinically used camptothecins, where 30-70% of the lactone is present in plasma [17] .
In conclusion, gimatecan showed high antitumor activity in several pediatric tumor models, supported by pharmacokinetic evidence of high oral disposition of the drug, present largely as the lactone form, with high and lasting distribution in tumor tissue. This particular pharmacological behavior suggests that gimatecan might be of interest in the treatment of pediatric solid tumors.
